JAB 6000
Alternative Names: JAB-6000Latest Information Update: 28 Sep 2023
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Cancer in China
- 20 Aug 2019 Preclinical trials in Cancer in China before August 2019 (Jacobio Pharmaceuticals pipeline, August 2019)
- 17 May 2018 Early research in Cancer in China (unspecified route)